Prevalence of the Use of Aspirin and Statins for Preventing Cardiovascular Events in the Colombian Population with Type 2 Diabetes Mellitus: Comparison of 2008 and 2018

Manuel E. Machado-Duque¹,², Diego Arturo Garcia², Melissa Hiromi Emura-Vélez², Andrés Gaviria-Mendoza¹,², and Jorge E. Machado-Alba¹

Abstract

Background: Type 2 diabetes mellitus (T2DM) greatly increases cardiovascular risk. Primary and secondary cardiovascular prevention lead to lower cardiovascular events, improved quality of life and lower costs related to complications. Objective: To estimate the proportion of patients with T2DM undergoing drug therapy for cardiovascular prevention (aspirin and statins) in Colombia and to describe the change in patterns of use between 2008 and 2018. Methods: This was a cross-sectional study comparing prescriptions for aspirin and statins in 2008 and in 2018 in outpatients diagnosed with T2DM. Records were obtained from a national drug claim database. The proportion of use of cardiovascular prevention drugs and antidiabetic drugs, medications for comorbidities and sociodemographic variables were analyzed for both periods. Results: In total, 26 742 patients in 2008 and 188 321 in 2018 with a diagnosis of T2DM treated with antidiabetic drugs were identified, among whom 57.5% and 44.2% received aspirin and 44.9% and 60.2% received statins, respectively. The use of high-intensity statins increased from 1.1% in 2008 to 95.2% in 2018. The probabilities of receiving drugs in 2008 and in 2018 were higher for men (OR: 1.12, 95% CI: 1.06-1.17 and OR: 1.26, 95% CI: 1.23-1.28, respectively), for those persons over 75 years of age (OR: 6.5, 95% CI: 5.3-7.9 and OR: 5.8, 95% CI: 5.4-6.2) and for those who also received clopidogrel (OR: 5.8, 95% CI: 4.4-7.6 and OR: 2.2, 95% CI: 2.1-2.4). Conclusions: The use of high-intensity statins in patients with T2DM has increased significantly in the last decade, which should reduce cardiovascular events, morbidity and mortality.

Keywords
Type 2 diabetes mellitus, cardiovascular diseases, aspirin, hydroxymethylglutaryl-CoA reductase inhibitors, hypolipidemic agents, pharmacoepidemiology

Introduction

Chronic noncommunicable diseases are currently considered an epidemic.¹-³ Among the leading causes of death globally are pathologies of cardiovascular origin, which are strongly linked to type 2 diabetes mellitus (T2DM), dyslipidemia, and high blood pressure (HBP). According to various reports, cardiovascular disease is the leading cause of death worldwide, including Latin America and Colombia.²⁻⁴

T2DM greatly increases cardiovascular risk.⁵,⁶ Globally, the population with T2DM numbers 476 million, and when standardized by age, the global prevalence of T2DM is 5.8%. In Colombia, the estimated prevalence is between 4% and 8%.⁷ In the absence of adequate control and preventive measures, the pathology of T2DM entails a higher incidence of acute myocardial infarction and other
cardiovascular conditions. Recommendations for cardiovascular prevention in this population include healthy lifestyle habits and pharmaceutical therapies for controlling blood sugar, blood pressure, dyslipidemia, and platelet aggregation. These last 2 therapies have also been used in primary cardiovascular prevention.

Primary and secondary cardiovascular prevention result in decreased cardiovascular events, improved quality of life and lower costs related to complications. However, despite guidelines and evidence supporting the efficacy and safety of lipid-lowering therapies, between 4% and 79% of patients with high cardiovascular risk and diabetes adhere to treatment, with a smaller percentage achieving glycemic control and serum cholesterol treatment goals. In the United States, less than half of patients receive the recommended therapies (aspirin, statins, blood pressure, and diabetes medications) for cardiovascular prevention.

In Colombia, only 38.6% of high-risk cardiovascular patients achieve cholesterol low density lipoprotein (LDL) goals, and 32.2% of patients who routinely receive aspirin have concomitant T2DM.

There is no current published data from Colombia regarding the prevalence of use of medications such as aspirin or statins among individuals with T2DM. From a pharmacoepidemiological perspective, understanding the changes in the patterns of medications over time is important for evaluating the national public health interventions. The purpose of this study was to estimate the proportion of people with T2DM receiving drug therapy for cardiovascular prevention (aspirin and statins for this study) in Colombia, to describe the changes from 2008 to 2018 and to identify possible variables associated with the use of these medications.

Methods

Study Design

A cross-sectional study was conducted. Data were obtained from a national drug claim database containing the records of approximately 6.5 million people, which represents 13.5% of the country’s total population. The dispensing information was from 5 different healthcare insurance companies (EPS) of the contributory regime (social health insurance for workers and families), which is present in all regions of Colombia.

The information in its entirety was obtained from the dispensing database of Audifarma SA, which has been used in multiple pharmacoepidemiological studies.

Participants and Setting

The study included all ambulatory patients over 18 years of age, of either sex, diagnosed with and treated for T2DM through the Health System of Colombia at 5 healthcare insurers and who had drug claims registered in the database; a patient was defined as having T2DM if he/she had a registered diagnosis (International Classification of Diseases-ICD10 codes: E110-E149) and received medications for T2DM continuously during the last quarters of 2008 and 2018 (dispensed each month). Exclusion criteria were not considered for this study.

Data Collection

After identification of the included patients, the following variables were determined:

1. Sociodemographic: age (according to groups: young adult: 18-44 years; middle adult: 45-64 years; older adult: 65-74 years; and elderly: over 75 years), sex and city of residence.
2. Diabetes control medications: (a) metformin; (b) sulfonylureas; (c) thiazolidinediones; (d) dipeptidyl peptidase 4 (DPP-4) inhibitors; (e) glucagon-like peptide-1 (GLP-1) receptor agonists; (f) sodium-glucose cotransporter-2 (SGLT-2) inhibitors; and (g) insulins.
3. Cardiovascular prevention medications: (a) prescription of any statin (high-intensity statins were categorized as atorvastatin doses ≥ 40 mg/day and rosuvastatin doses ≥ 20 mg/day); (b) antiplatelet drugs: use of aspirin and use of P2Y12 inhibitors.
4. Other comediations: antihypertensive, antiulcer, antidepressant, antianginal and anticoagulant medications, nonsteroidal anti-inflammatory drugs (NSAIDs), fibrates, levothyroxine, beta 2-adrenergic agonists and inhaled anticholinergics.

Statistical Analysis

A database was created in Microsoft Excel 2016 with the identified variables. The analyses were performed in SPSS v24.0 (IBM, USA). Frequencies and proportions of the categorical variables were established in order to determine the prevalence of medication use for cardiovascular prevention in patients with T2DM. Bivariate analyses were performed to establish possible associations with cardiovascular prevention drug prescriptions (aspirin and statins together) among the included T2DM patients, and the subsequent multivariate analysis was designed to adjust the associated variables (comparing those T2DM patients with prescriptions for these medications to those without prescriptions). P values less than .05 indicated statistical significance.

Bioethical Considerations

The study was approved by the Bioethics Committee of the Universidad Tecnológica de Pereira (Colombia, South
America) in the category of “risk-free research” following the principles established by the Declaration of Helsinki. Access to dispensing data was obtained with the permission of Audifarma S.A.

Results

A total of 26,741 participants were identified from the last quarter of 2008, mostly from the Bogotá-Cundinamarca, Central and Caribbean regions, and 188,321 patients with a diagnosis of T2DM and receiving pharmacological treatment were identified from the last quarter of 2018, mainly from the Bogotá-Cundinamarca, Pacific, and Central regions. At both timepoints, there was a slightly more women than men, and the average patient age was lower in 2018 than in 2008. Among comediations, antihypertensives were predominant (mainly angiotensin II receptor blockers [ARB-II] and angiotensin-converting enzyme inhibitor [ACEI]), followed by antiulcer drugs such as proton pump inhibitors. Table 1 provides the sociodemographic characteristics with comediations for the 2 groups of patients.

Antidiabetic Drugs

The most-prescribed antidiabetic drugs for 2008 were metformin (n: 20,545; 76.8%), sulfonylureas (n: 12,795; 47.5%) and insulins (n: 9,065; 34.0%) and for 2018 were metformin (n: 16,7415; 87.7%), insulins (n: 79,857; 42.4%) and DPP-4 inhibitors (n: 32,596; 17.2%). Prescription data for antidiabetic drugs are provided in Table 2. A change in the pattern of use of human insulins was observed: the share of patients receiving these drugs decreased from 31.5% in 2008 to 3.5% in 2018, while the use of insulin analogs increased from 2.5% in 2008 to 38.9% in 2018. Table 3 provides the patterns of use of antidiabetic drugs by group and in combinations.

Use of Aspirin and Statins (Prevention of Cardiovascular Risk)

Among lipid-lowering drugs, the most-prescribed statin in 2008 was lovastatin (98.7% of cases); while atorvastatin was the most-prescribed in 2018 (85.3%) (proportions based on the total number of patients prescribed statins). The drugs used to reduce cardiovascular risk and the prescription frequencies of aspirin and statins are provided in Table 4. Aspirin use decreased from 57.5% in 2008 to 44.2% in 2018, and the use of all statins increased from 24.49% in 2008 to 60.2% in 2018. Notably, the high-intensity statins increased from 1.1% in 2008 to 95.2% in 2018, while the combined use of aspirin + statin continued at about 32% at both times.

Multivariate Analysis

Binary logistic regression revealed statistically significant positive associations of using aspirin and statins in combination in 2008 with male gender (OR: 1.116; 95% CI: 1.056-1.179), age older than 75 years (OR: 6.484; 95% CI: 5.296-7.938) and treatment with clopidogrel (OR: 5.854; 95% CI: 4.463-7.678). In 2018, male patients (OR: 1.262; 95% CI: 1.235-1.289), those older than 75 years of age (OR: 5.819; 95% CI: 5.410-6.258) and those receiving antihypertensive treatment had greater probabilities of receiving prescriptions for aspirin and statins. On the other hand, people receiving fibrates (OR: 0.232; 95% CI: 0.218-0.246) or anticoagulant drugs had a lower probability of receiving the medications for the prevention of cardiovascular risk (see Table 5).

Discussion

General Findings

In 2008 and 2018, one third of patients with T2DM received drugs for the prevention of cardiovascular risk (the combination of aspirin and statins). Between these 2 time points, the proportion of patients receiving antplatelet prescriptions decreased, whereas there was an increase in prescriptions for lipid-lowering agents. Cardiovascular secondary prevention through the use of aspirin and statins benefits patients by reducing cardiovascular events, and different clinical practice guidelines support the prescription of this combination to reduce morbidity and mortality from cardiovascular-related causes.

Most T2DM patients in 2008 and 2018 were women, in accordance with previous epidemiological analyses in Colombia, but men were more likely to receive aspirin or statins, which is consistent with a report by Alfredsson J et al where men had a higher probability of being prescribed aspirin (81.0% vs 72.5%) or a statin (82.7% vs 73.0%). Notably, in a number of different age groups, epidemiological studies indicate that the cardiovascular risk of women with T2DM is at least 25% greater than that of men. This can be explained by differences in the perceived risk of patients and the need for therapy, representing a current gap in pharmacological management, especially in women with T2DM.

The lower mean age of patients with T2DM in 2018 could indicate an earlier diagnosis from screening programs and better care of noncommunicable chronic diseases such as T2DM, dyslipidemia and HBP. In addition, patients older than 75 years were more likely to receive drugs for secondary prevention, possibly due to evidence that age is one of the most important nonmodifiable cardiovascular risk factors. Ramos et al showed that the use of statins reduced atherosclerotic cardiovascular events and mortality from all causes in the population between 75 and...
84 years of age; however, in patients older than 85 years, the findings were not significant. In addition, in the PURE study in Latin America, a low prevalence of statin use was found (4% of joint use of cardiovascular prevention drugs), but among those evaluated, patients older than 65 years had a greater probability of receiving them, similar to the present findings. This group of patients constitutes a challenge in the clinical setting, and more studies are needed to help focus cardiovascular prevention, especially in those who continue in a good vital state.26

Table 1. Sociodemographic Characteristics and Comedications of Patients with Type 2 Diabetes Mellitus in the Last Trimesters of 2008 and 2018.

| Sociodemographic characteristics and comedication | Last quarter 2008 | Last quarter 2018 |
|---------------------------------------------------|------------------|------------------|
|                                                   | n=26741          | n=188231         |
| Sex                                               |                  |                  |
| Female                                            | 15 096 / 56.5    | 108 789 / 57.8   |
| Age (years)                                       | 69.4 / 13.6      | 63.8 / 13.5      |
| Regions (Colombia)                                |                  |                  |
| Amazonia-Orinoquia                                | 43 / 0.2         | 640 / 0.3        |
| Bogota-Cundinamarca                               | 13 546 / 50.7    | 66 879 / 35.5    |
| Caribbean                                         | 4000 / 15.0      | 32 895 / 17.5    |
| Central                                           | 6 155 / 23.0     | 40 314 / 21.4    |
| West region                                       | 1 509 / 5.6      | 6 438 / 3.4      |
| Pacific                                           | 1 488 / 5.6      | 41 155 / 21.9    |
| Comedications                                     |                  |                  |
| Analgesics                                        |                  |                  |
| NSAIDb                                            | 3 798 / 14.2     | 16 321 / 8.7     |
| Antianginal gents                                 | 357 / 1.3        | 1 370 / 0.7      |
| Anticoagulants                                    |                  |                  |
| Apixaban                                          | —                 | 781 / 0.4        |
| Dabigatran                                        | —                 | 4 51 / 0.2       |
| LMWFHf                                            | 2 40 / 0.9       | 2 393 / 1.3      |
| UFHf                                              | 20 / 0.1         | 617 / 0.3        |
| Rivaroxaban                                       | —                 | 1 378 / 0.7      |
| Warfarin                                          | 339 / 1.3        | 1 250 / 0.7      |
| Antidepressants                                   |                  |                  |
| Serotonin uptake inhibitor                        | 1 077 / 4.0      | 11 335 / 6.0     |
| Serotonin and noradrenaline uptake inhibitor      | 6 / 0             | 545 / 0.3        |
| Tricyclic                                         | 179 / 0.7        | 2 206 / 1.2      |
| Antihypertensives                                 |                  |                  |
| ARB-IIe                                           | 8 418 / 31.5     | 97 253 / 51.6    |
| β-blockers                                        | 5 338 / 20       | 41 864 / 22.2    |
| Alpha-1 antagonist                                | 884 / 3.3        | 7 418 / 3.9      |
| Clonidine                                         | 687 / 2.6        | 4 791 / 2.5      |
| Calcium Channel Blockers                          | 7 109 / 26.6     | 50 353 / 26.7    |
| ACEIf                                            | 10 716 / 40.1    | 28 054 / 14.9    |
| Antiulcer                                         |                  |                  |
| Antacids                                          | 1 181 / 4.4      | 10 288 / 5.5     |
| Bismuth subsalicylate                             | —                 | 6 / 0             |
| PPIf                                             | 7 662 / 28.7     | 48 169 / 25.6    |
| Ranitidine                                        | 6 21 / 2.3       | 6 912 / 3.7      |
| Sucralfate                                        | 1 82 / 0.7       | 2 743 / 1.5      |
| Levothyroxine                                     |                  |                  |
| Levothyroxine                                     | —                 | 458 / 0.2        |
| Bronchodilators                                   |                  |                  |
| Anticholinergic                                   | 1 027 / 3.8      | 7 845 / 4.2      |
| β2 adrenergic agonist                             | 1 095 / 4.1      | 7 188 / 3.8      |
| Fibrates                                          | 40 408 / 15.1    | 12 272 / 6.5     |

*Standard deviation. bNonsteroidal anti-inflammatory drugs. cLow-molecular-weight fragment of heparin. dUnfractionated heparin. eAngiotensin II receptor blockers. fAngiotensin-converting enzyme inhibitor. gProton Pump Inhibitors.

Use of Aspirin and Statins in the T2DM Population

There was also a marked increase in the prescription of high-intensity statins by 2018, which could be related to accumulating evidence on the benefits of these drugs for reducing mortality27 and major cardiovascular events (acute coronary syndrome, cardiac revascularization, and death of cardiovascular origin) compared with statins of moderate or low intensity. The increased prescription of
Table 2. Prescription of Antidiabetic Drugs for Patients with Type 2 Diabetes Mellitus in the Last Trimesters of 2008 and 2018.

| Antidiabetic drugs       | Pharmaceutical form | Last quarter 2008 | Last quarter 2018 |
|--------------------------|---------------------|-------------------|-------------------|
|                          |                     | n = 26741 %       | n = 188231 %      |
| **Biguanides**           |                     |                   |                   |
| Metformin 500 mg         | 2                   | 0                 | 14388 7.6         |
| Metformin 850 mg         | 20533               | 76.8              | 119781 63.6       |
| Metformin 1000 mg        | 1                   | 0                 | 7266 3.9          |
| **Sulfonylureas**        |                     |                   |                   |
| Glyburide 5 mg           | 12754               | 47.4              | 14812 7.9         |
| Gliclazide 60 mg         | —                   | —                 | 95 0.1            |
| Gliclazide 80 mg         | 4                   | 0                 | —                 |
| Glimepiride 2 mg         | 11                  | 0                 | 962 0.5           |
| Glimepiride 4 mg         | 26                  | 0.1               | 469 0.2           |
| **DPP-4 Inhibitors**     |                     |                   |                   |
| Linagliptin 5 mg         | —                   | —                 | 4221 2.2          |
| Linagliptin/Metformin 2.5/500 mg | — | — | 401 0.2 |
| Linagliptin/Metformin 2.5/850 mg | — | — | 796 0.4 |
| Linagliptin/Metformin 2.5/1000 mg | — | — | 2200 1.2 |
| Saxagliptin 2.5 mg       | —                   | —                 | 38 0              |
| Saxagliptin 5 mg         | —                   | —                 | 163 0.1           |
| Saxagliptin/Metformin 2.5/1000 mg | — | — | 1493 0.8 |
| Saxagliptin/Metformin 5/1000 mg | — | — | 442 0.2 |
| **Sitagliptin**          |                     |                   |                   |
| Sitagliptin 25 mg        | —                   | —                 | 51 0              |
| Sitagliptin 50 mg        | 36                  | 0.1               | 944 0.5           |
| Sitagliptin/Metformin 50/500 mg | 6 | 0 | 503 0.3 |
| Sitagliptin/Metformin 50/850 mg | — | — | 1781 0.9 |
| Sitagliptin/Metformin 50/1000 mg | 3 | 0 | 10272 5.4 |
| **Vildagliptin**         |                     |                   |                   |
| Vildagliptin 50 mg       | —                   | —                 | 925 0.5           |
| Vildagliptin/Metformin 50/500 mg | — | — | 339 0.2 |
| Vildagliptin/Metformin 50/850 mg | — | — | 1230 0.7 |
| Vildagliptin/Metformin 50/1000 mg | — | — | 4902 2.6 |
| **GLP-1 agonist**        |                     |                   |                   |
| Liraglutide Pen 6 mg/mL/3 mL | — | — | 2646 1.4 |
| **SGLT-2 Inhibitors**    |                     |                   |                   |
| Canagliflozin 300 mg     | —                   | —                 | 20 0              |
| Dapagliflozin 10 mg      | —                   | —                 | 979 0.5           |
| Dapagliflozin/Metformin 5/1000 mg | — | — | 772 0.4 |
| Dapagliflozin/Metformin 10/1000 mg | — | — | 428 0.2 |
| Empagliflozin 10 mg      | —                   | —                 | 652 0.3           |
| Insulin analogs          |                     |                   |                   |
| Aspartat Pen 100 UI/mL/3 mL | 18 | 0.1 | 5798 3.1 |
| Glulisine Pen 100 UI/mL/3 mL | 1 | 0 | 16483 8.8 |
| Glulisine Vial 100 UI/mL/10 mL | 57 | 0.2 | 1499 0.8 |
| Lispro Cartridge 100 UI/mL/3 mL | 52 | 0.2 | 62 0 |
| Lispro Vial 100 UI/mL/10 mL | 182 | 0.7 | 408 0.2 |
| Degludec Pen 100 UI/mL/3 mL | — | — | 5127 2.7 |
| Degludec Pen 100 UI/mL/3 mL | — | — | 4090 2.2 |
| Glargine Pen 100 UI/mL/3 mL | 4 | 0 | 35722 19 |
| Glargine Vial 100 UI/mL/10 mL | 337 | 1.3 | 4038 2.1 |

*Dipeptidyl-Peptidase 4 Inhibitor, ^Glucagon-like peptide-1 receptor agonists, ºSodium-glucose transport protein 2 Inhibitors.
high-intensity statins may also be due to their inclusion on the list of medications in the benefit plan of the Colombian health system,\(^29\) as well as their recommendation by the clinical practice guidelines of the Ministry of Health of Colombia in 2014. Previously, no such guidelines existed, and there were no specific recommendations for the country.\(^30\) However, despite their favorable cardiovascular effects, high-intensity statins are associated with increases of up to 0.4% \((P = .0002)\) in the levels of glycosylated hemoglobin (HbA1c) in patients with T2DM as well as an increased risk of de novo diabetes compared with low-intensity statins.\(^31\) Therefore, patients risk factors should be reviewed to establish the risk/benefit ratio, and guide the therapy to achieve adequate metabolic control.\(^32,33\)

Approximately half of the patients received aspirin; however, only 2% were jointly prescribed clopidogrel, which would indicate that most of the population was receiving aspirin for primary prevention of cardiovascular risk. However, the use of aspirin after the year of presentation of acute coronary syndrome cannot be ruled out, and dual antiplatelet therapy would not be indicated in this case.\(^34\) A study in Japan found no evidence that the use of aspirin in low doses for primary prevention in patients with T2DM prevents any cardiovascular event at 10 years, but a significant increase in the risk of gastrointestinal bleeding was observed.\(^35,36\) In addition, although the ASCEND study demonstrated the efficacy of aspirin for the primary prevention of serious vascular events, it also found a 29% higher risk of major bleeding in Caucasian patients\(^17\); therefore, the risk/benefit ratio of antiplatelet drugs in primary prevention in patients with high cardiovascular risk, especially those with T2DM, requires further study. The large number of patients receiving aspirin in 2008 could be a medical behavior supported by the recommendations of the 2007 guidelines of the American Heart Association (AHA) and the American Diabetes Association (ADA) for primary prevention in patients with T2DM and high cardiovascular risk.\(^38\) However, the clinical practice guideline of the Ministry of Health of Colombia in 2015 advises against the use of aspirin for primary prevention in T2DM patients.\(^39\)

**Diabetes Treatment**

With respect to T2DM treatment, the prescription of sulfonylureas decreased markedly in 2018 compared with 2008 (8.6% vs 47.8%). In Colombia, a decrease in the prescription of glyburide has been observed (from 64.9% in 2005 to 21.8% in 2015),\(^17,38\) which is probably related to its association with cardiovascular events, its frequent undesirable effects and the emergence of new antidiabetic drugs such as SGLT-2 inhibitors, GLP-1 receptor agonists and DPP-4 inhibitors. These latter drugs have shown cardiovascular benefits or at least do not increase the risk of cardiovascular events; they are also associated with fewer hypoglycemic events.\(^40\)

The prescription of DPP-4 inhibitors increased significantly between 2008 and 2018 because these drugs are now the second line of treatment according to the recommendations of the clinical practice guidelines for Colombia.\(^4\) In addition, the proportion of new antidiabetic drugs, such as GLP-1 receptor agonists and SGLT-2

---

**Table 3.** Prescription of Antidiabetic Drugs by Group and in Combination with Metformin for Patients with Type 2 Diabetes Mellitus in the Last Trimesters of 2008 and 2018.

| Antidiabetic drugs       | Last quarter 2008 | Last quarter 2018 |
|--------------------------|-------------------|-------------------|
|                          | n = 26741 %       | n = 188231 %      |
| Metformin                |                   |                   |
|                         | Metformin (monotherapy) | 20545 76.8 | 159965 84.9 |
|                         | Combined         | 20545 76.8       | 134977 71.7 |
|                         | DPP-4 inhibitor\(^a\) | 24988 13.3       | 23866 12.7 |
|                         | SGLT-2 Inhibitor\(^b\) |            | 1181 0.6 |
| Other oral antidiabetic drugs |                |                   |
| Sulfonylureas            | 12790 47.8       | 16250 8.6        |
| DPP-4 Inhibitors         | 48 0.2           | 31308 16.6       |
| GLP-1 agonist\(^c\)      |                 | 2646 1.4         |
| SGLT-2 Inhibitor         |                 | 4098 2.2         |
| Insulin                  | 6627 24.8        | 55191 29.3       |
|                         | Regular          | 2223 8.3         | 1382 0.7 |
|                         | NPH              | 6191 23.2        | 5248 2.8 |
|                         | Short acting analog | 300 1.1 | 23846 12.7 |
|                         | Long acting analog | 340 1.3 | 47824 25.4 |

\(^a\)Dipeptidyl-Peptidase 4 Inhibitor, \(^b\)Sodium-glucose transport protein 2 Inhibitors, \(^c\)Glucagon-like peptide-1 receptor agonists.
inhibitors, increased. These drugs have a significant impact on major cardiovascular events in high-risk patients and are part of the second line of management based on the recommendations of the ADA for patients with T2DM and atherosclerotic cardiovascular disease or chronic kidney disease. Their use should augment the effect of statins and aspirin on cardiovascular risk in patients who are receiving drugs for primary or secondary prevention because of the potential benefits for reducing cardiovascular events.

Table 4. Prescription of Drugs for Cardiovascular Prevention in Patients with Type 2 Diabetes Mellitus in the Last Trimesters of 2008 and 2018.

| Cardiovascular prevention drugs* | Last quarter 2008 | Last quarter 2018 |
|----------------------------------|------------------|-------------------|
|                                  | n    | %   | n    | %   |
| **Platelet aggregation inhibitors** |      |     |      |     |
| Aspirin 100 mg                   | 15379| 57.5| 83280| 44.2|
| Clopidogrel 75 mg                | 259  | 1.1 | 4270 | 2.3 |
| Clopidogrel/Aspirin 75/100 mg    | —    | —   | 4    | 0.0 |
| Prasugrel 10 mg                  | —    | —   | 56   | 0.0 |
| Ticagrelol 90 mg                 | —    | —   | 300  | 0.2 |
| **Anticholesteremic agents**     |      |     |      |     |
| Atorvastatin 10 mg               | 7    | 0.0 | 2619 | 1.4 |
| Atorvastatin 20 mg               | 57   | 0.2 | 40669| 21.6|
| Atorvastatin 40 mg               | 53   | 0.2 | 53426| 28.4|
| Atorvastatin 80 mg               | 2    | 0.0 | 1457 | 0.8 |
| Atorvastatin/Ezetimibe           |      |     | 13   | 0.0 |
| Lovastatin 20 mg                 | 11864| 44.4| 5799 | 3.1 |
| Pravastatin 20 mg                | 1    | 0.0 | 7    | 0.0 |
| Pravastatin 40 mg                | 4    | 0.0 | —    | —   |
| Rosuvastatin 10 mg               | 7    | 0.0 | 671  | 0.4 |
| Rosuvastatin 20 mg               | 9    | 0.0 | 4626 | 2.5 |
| Rosuvastatin 40 mg               | —    | —   | 8640 | 4.6 |
| Rosuvastatin/Ezetimibe 10/10 mg  | —    | —   | 22   | 0.0 |
| Rosuvastatin/Ezetimibe 20/10 mg  | —    | —   | 123  | 0.1 |
| Rosuvastatin/Ezetimibe 40/10 mg  | —    | —   | 399  | 0.2 |
| Rosuvastatin/Ezetimibe 5/135 mg  | —    | —   | 42   | 0.0 |
| Rosuvastatin/Fenofibrate 10/135 mg | —  | —  | 520  | 0.3 |
| Rosuvastatin/Ezetimibe 20/135 mg| —    | —   | 1326 | 0.7 |
| Simvastatin 10 mg                | 1    | 0.0 | —    | —   |
| Simvastatin 20 mg                | —    | —   | 65   | 0.0 |
| Simvastatin 40 mg                | 5    | 0.0 | 91   | 0.0 |
| Simvastatin 80 mg                | —    | —   | 7    | 0.0 |
| Simvastatin/Ezetimibe 10/10 mg   | 1    | 0.0 | 10   | 0.0 |
| Simvastatin/Ezetimibe 20/10 mg   | 23   | 0.1 | 66   | 0.0 |
| Simvastatin/Ezetimibe 40/10 mg   | 20   | 0.1 | 87   | 0.0 |
| Simvastatin/Ezetimibe 80/10 mg   | —    | —   | 27   | 0.0 |
| **Aspirin and statins prescription** |      |     |      |     |
| Aspirin 100 mg                   | 15379| 57.5| 83280| 44.2|
| **P2Y12 antagonist**             |    |     | 113315| 60.2|
| Statin All 12/010 mg             | 259  | 1.1 | 4597 | 2.4 |
| Statin 12/010 mg                 | 12010| 44.9| 113315| 60.2|
| High Intensity*                  | 132  | 1.12| 107838| 95.22|
| Ezetimibe                        | —    | —   | 870  | 0.5 |

*Tablets, unless otherwise indicated.

*Total number of patients with high intensity statins/total number of patients with statins.
Limitations

This research is limited by the cross-sectional design which compares 2 points in time without analysis of the trends between years. We were unable to access the clinical records of patients; this limited the ability to define the difference between primary and secondary prevention strategies. The findings of this study should be applied to populations with similar insurance characteristics and access to medications. Finally, the strength of this study is the evaluation of the entire population with T2DM affiliated with these insurers to report the changes in national pharmacoepidemiological patterns. The data represents more than 13% of the Colombian population.

Conclusions

With the introduction of national clinical guidelines in Colombia, the management of cardiovascular risk in patients with T2DM seems to be more consistent with international recommendations. The use of aspirin as a prevention measure for cardiovascular risk in patients with T2DM is decreasing, while the use of statins, especially high-intensity statins, has increased over the last decade. The probability of receiving medication for prevention was higher among men, those older than 75 years and patients diagnosed with hypertension. In addition, new antidiabetic drugs that have shown neutral or positive effects on cardiovascular risk are being used more frequently. The changes in drug prescriptions observed in this study suggest that the clinical practice guidelines for the management of patients with T2DM have been adequately implemented. Further research is necessary to understand the findings from this study in relationship to patient and health system outcomes.

Acknowledgments

To Carlos Tovar for his support in the generation of the database.

Table 5. Multivariate Analysis of the Variables Associated with Joint Prescription of Acetylsalicylic Acid and Statins for Patients with Type 2 Diabetes Mellitus in the Last Trimesters of 2008 and 2018.

| Multivariate analysis | Last quarter 2008 | 95% CI | Last quarter 2018 | 95% CI |
|-----------------------|-------------------|--------|-------------------|--------|
|                       | P                 | OR     | Lower             | Upper             | P                 | OR     | Lower             | Upper             |
| Sex (Male)            | .001              | 1.116  | 1.056             | 1.179            | .001              | 1.262  | 1.235             | 1.289            |
| Age                   |                   |        |                   |                   |                   |        |                   |                   |
| 18-44 years           |                   |        |                   |                   |                   |        |                   |                   |
| 45-59 years           | .001              | 2.579  | 2.087             | 3.186            | .001              | 3.776  | 3.514             | 4.057            |
| 60-74 years           | .001              | 5.113  | 4.18              | 6.255            | .001              | 5.939  | 5.534             | 6.373            |
| ≥75 years             | .001              | 6.484  | 5.296             | 7.938            | .001              | 5.819  | 5.41              | 6.258            |
| Metformin             | .001              | 1.56   | 1.453             | 1.675            | .001              | 1.499  | 1.449             | 1.55             |
| DPP-4 inhibitors      |                   |        |                   |                   |                   |        |                   |                   |
| Sulfonylureas         |                   |        |                   |                   |                   |        |                   |                   |
| SGLT-2 inhibitors     |                   |        |                   |                   |                   |        |                   |                   |
| GLP-1 agonist         |                   |        |                   |                   |                   |        |                   |                   |
| Insulin               | .001              | 1.809  | 1.695             | 1.93             | .001              | 1.623  | 1.582             | 1.666            |
| Clopidogrel           | .001              | 5.854  | 4.463             | 7.678            | .001              | 2.238  | 2.086             | 2.401            |
| NSAID                 | .001              | 1.132  | 1.049             | 1.223            | .001              | 0.149  | 0.133             | 0.167            |
| Direct oral anticoagulant |        |        |                   |                   |                   |        |                   |                   |
| Anticholinergics      | .078              | 0.87   | 0.745             | 1.016            | .02               | 1.07   | 1.011             | 1.133            |
| ARB-II                | .001              | 1.246  | 1.172             | 1.326            | .001              | 2.027  | 1.975             | 2.081            |
| β-blockers            |                   |        |                   |                   |                   |        |                   |                   |
| β-2 adrenergics       | .007              | 1.226  | 1.057             | 1.422            | .002              | 0.91   | 0.857             | 0.966            |
| Fibrates              | .078              | 1.069  | 0.992             | 1.152            | .001              | 0.232  | 0.218             | 0.246            |
| Heparins              |                   |        |                   |                   |                   |        |                   |                   |
| PPI                   | .001              | 1.14   | 1.074             | 1.21             | .001              | 1.197  | 1.169             | 1.226            |
| ACEI                  | .001              | 1.16   | 1.094             | 1.23             | .001              | 2.308  | 2.235             | 2.384            |
| Nitrates              |                   |        |                   |                   |                   |        |                   |                   |
| Other antihypertensive drug | .086  | 0.949  | 0.894             | 1.008            | .001              | 1.233  | 1.205             | 1.262            |
| Warfarine             |                   |        |                   |                   |                   |        |                   |                   |

An analysis was performed by adjusting associations in 2008 and another in 2018.

aConfidence interval, bDipeptidyl-Peptidase 4 Inhibitor, cSodium-glucose cotransporter-2 inhibitors, dGlucagon-like peptide-1 receptor agonists, eNonsteroidal anti-inflammatory drugs, fAngiotensin II receptor blockers, gProton Pump Inhibitor, hAngiotensin-converting enzyme inhibitor.
Author Contributions
Jorge Enrique Machado-Alba participated in Conceptualization, investigation, methodology, project administration, resources, supervision, validation, writing review and editing. Manuel Enrique Machado-Duque participated in data curation, formal analysis, investigation, methodology, validation, writing original and review and editing. Andres Gaviria-Mendoza participated in formal analysis, methodology, validation, visualization, writing original draft and editing. Diego Arturo Garcia participated in formal analysis, methodology, validation, visualization, writing original draft and editing. Melissa Hiromi Emura-Vélez participated in formal analysis, methodology, validation, visualization, writing original draft and editing.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Statement of Supporting Data
dx.doi.org/10.17504/protocols.io.94yh8xw

ORCID iD
Jorge E. Machado-Alba https://orcid.org/0000-0002-8455-0936

References
1. World Health Organization. About cardiovascular diseases, Cardiovascular disease. 2019. Accessed January 2019. https://www.who.int/cardiovascular_diseases/about_cv/6/en/.
2. Ministerio de Salud y Protección Social. Análisis de Situación de Salud (ASIS) Colombia, 2018. Dirección de Epidemiología y Demografía Bogotá D.C. Colombia 2019. Accessed January 2019. https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/ED/PSP/asis-colombia-2018.pdf.
3. World Health Organization. Noncommunicable diseases country profiles 2018. Geneva. 2018. Accessed January 2019. https://www.who.int/nmh/publications/ncd-profiles-2018/en/.
4. Aschner PM, Munoz OM, Giron D, et al. Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults. Colomb Med (Cali). 2016;47:109-131.
5. Machado-Alba JE, Machado-Duque ME. Cardiovascular risk factors prevalence among patients with dyslipidemia in Colombia. Rev Peru Med Exp Salud Publica. 2013;30(2):205-211.
6. Himmen D, Kruger DF. Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials. Diabetes Metab Syndr Obes. 2019;12:447-455. doi:10.2147/DMSO.S188705
7. Aschner P. Epidemiología de la diabetes en Colombia. Av Diabetol. 2010;26(2):95-100.
8. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACP/H/AGS/APhA/ASP/ NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):e285-e350. doi:10.1016/j.jacc.2018.11.003
9. Newman JD, Schwartzbard AZ, Weintraub HS, et al. Primary prevention of cardiovascular disease in diabetes mellitus. J Am Coll Cardiol. 2017;70(7):883-893.
10. Jones Freeman EL. Strategies for optimizing treatment outcomes. J Manag Care Pharm. 2003;9(1 Suppl):20-23. doi:10.18553/jmcp.2003.9.s1.20
11. Mindell J, Aresu M, Zaninotto P, et al. Improving lipid profiles and increasing use of lipid-lowering therapy in England: results from a national cross-sectional survey - 2006. Clin Endocrinol (Oxf). 2011;75(5):621-627.
12. Primasteta P, Poultet NR. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ. 2000;321(7272):1322-1325.
13. Cong L, Ren Y, Hou T, et al. Use of cardiovascular drugs for primary and secondary prevention of cardiovascular disease among rural-dwelling older chinese adults. Front Pharmacol. 2020;11:608136.
14. Ali MK, Bullard KM, Saadine JB, et al. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med. 2013;368(17):1613-1624.
15. Machado-Alba JE, Murillo-Munoz MM, Machado-Duque ME. Effectiveness of lipid-lowering therapy among a sample of patients in Colombia. Rev Panam Salud Publica. 2013; 33(6):383-390.
16. Machado-Alba JE, Garcia S, Calvo-Torres LF, et al. Patrones de prescripción del ácido acetilsalicílico. Rev Colomb Cardiol. 2015;22(3):127-135.
17. Machado Alba JE, Moncada Escobar JC, Mesa Escobar G. Antidiabetic drugs prescription patterns among a group of patients in Colombia. Rev Panam Salud Publica. 2007;22:124-131.
18. Gaviria-Mendoza A, Sánchez-Duque JA, Medina-Morales DA, et al. Prescription patterns and costs of antidiabetic medications in a large group of patients. Prim Care Diabetes. 2018;12:184-191.
19. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-1860.
20. Alfredsson J, Green JB, Stevens SR, et al. Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: a report from TECOS. Diabetes Obes Metab. 2018;20:2379-2388.
21. Huebschmann AG, Huxley RR, Kohrt WM, et al. Sex differences in the burden of type 2 diabetes and cardiovascular risk across the life course. Diabetologia. 2019;62:1761-1772.
22. de Jong M, Vos RC, de Ritter R, et al. Sex differences in cardiovascular risk management for people with diabetes in primary care: a cross-sectional study. BJGP Open. 2019;3:bigopen19X101645.
23. Wright AK, Kontopantelis E, Emsley R, et al. Cardiovascular risk and risk factor management in type 2 diabetes mellitus. *Circulation*. 2019;139(24):2742-2753.

24. Chung S, Zhao B, Lauderdale D, et al. Initiation of treatment for incident diabetes: evidence from the electronic health records in an ambulatory care setting. *Prim Care Diabetes*. 2015;9(1):23-30.

25. Avezum A, Oliveira GBF, Lanas F, et al. Secondary CV prevention in South America in a community setting: the PURE study. *Glob Heart*. 2017;12:305-313.

26. Ramos R, Comas-Cufi M, Martí-Lluch R, et al. Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study. *BMJ*. 2018;362:k3359.

27. Rodriguez F, Maron DJ, Knowles JW, et al. Association between intensity of statin therapy and mortality in patients with atherosclerotic cardiovascular disease. *JAMA Cardiol*. 2017;2(1):47-54.

28. Liu Z, Xu Y, Hao H, et al. Efficacy of high intensity atorvastatin versus moderate intensity atorvastatin for acute coronary syndrome patients with diabetes mellitus. *Int J Cardiol*. 2016;222:22-26.

29. Ministerio de Salud y Protección Social. Resolución Número 5521 de 2013. Colombia. 2013. Accessed January 2019. https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDED/E/DI/Resolucion-5521-de-2013.pdf.

30. Ministerio de Salud y Protección Social. Guía de Práctica Clínica (GPC) para la prevención, detección temprana, diagnóstico, tratamiento y seguimiento de las dislipidemias en la población mayor de 18 años. Guía para profesionales de la salud 2014 - Guía No. 27. Bogotá D.C. 2014. Accessed January 2021. https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/INEC/IETS/GPC-Dislipidemi-completa.pdf.

31. Ooba N, Tanaka S, Yasukawa Y, et al. Effect of high-potency statins on HbA1c in patients with or without diabetes mellitus. *J Pharm Health Care Sci*. 2016;2:8.

32. Maki KC, Diwadkar-Navsariwala V, Kramer MW. Statin use and risk for type 2 diabetes: what clinicians should know. *Postgrad Med*. 2018;130(2):166-172.

33. Zigmont VA, Shoben AB, Lu B, et al. Statin users have an elevated risk of dysglycemia and new-onset-diabetes. *Diabetes Metab Res Rev*. 2019;35:e3189.

34. Bittl JA, Baber U, Bradley SM, et al. Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. *Circulation*. 2016;134(10):e156-e178.

35. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. *JAMA*. 2008;300(18):2134-2141.

36. Saito Y, Okada S, Ogawa H, et al. Low-dose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes mellitus: 10-year follow-up of a randomized controlled trial. *Circulation*. 2017;135(7):659-670.

37. Bowman L, Mafham M, Wallendszus K, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. *N Engl J Med*. 2018;379(16):1529-1539.

38. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. *Diabetes Care*. 2007;30(1):162-172.

39. Ministerio de Salud y Protección Social. Guía de práctica clínica para el diagnóstico, tratamiento y seguimiento de la diabetes mellitus tipo 2 en la población mayor de 18 años. Sistema General de Seguridad Social en Salud – Colombia. Guia para profesionales de la salud 2015 - Guía No. GPC-2015-5. Bogotá D.C. 2015. Accessed January 2021. http://gpc.minsalud.gov.co/gpc_sites/Repositorio/Conv_637/GPC_diabetes/DIASTES_TIPO_2_COMPLETA.pdf.

40. Douras A, Dell’Aniello S, Yu OHY, et al. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study. *BMJ*. 2018;362:k2693.

41. Marso SP, Daniels GH, Brown-Flagens K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2016;375:311-322.

42. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med*. 2017;377:644-657.

43. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin and the risk of cardiovascular and renal events in type 2 diabetes. *N Engl J Med*. 2015;373:2117-2128.

44. American Diabetes Association. 1. Improving care and promoting health in populations: standards of medical care in diabetes-2018. *Diabetes Care*. 2018;41:S7-S12.

45. Anholm C, Kumarathurai P, Pedersen LR, et al. Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial. *Atherosclerosis*. 2019;288:60-66.

46. Giugliano D, Maiorino MI, Bellastella G, et al. Type 2 diabetes and cardiovascular prevention: the dogmas disputed. *Endocrine*. 2018;60(2):224-228.